GlassScriptPhysician profile
Pankaj R Desai
NPI 1194790105
$18,483.66
in general payments reported to CMS, 2019-2025
54 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,224 · 2020: $2,737 · 2021: $1,638 · 2022: $2,145 · 2023: $2,272 · 2024: $5,543 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,196 · Consulting Fee: $2,000 · Travel and Lodging: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,196.41 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $1,542.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,673.99 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $1,985.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,300.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,100.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $949.68 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Glaxosmithkline, LLC. | $888.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $793.38 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $750.83 | 2019-2022 | |
| Pfizer INC. | $599.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $471.19 | 2019-2024 | Trintellix |
| Abbvie INC. | $388.88 | 2021-2025 | Qulipta |
| Idorsia Pharmaceuticals US INC | $353.33 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $330.36 | 2019-2022 | |
| Amarin Pharma, INC. | $305.62 | 2019-2022 | |
| Allergan, INC. | $292.35 | 2019-2020 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.